Study guide
4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol
AHA ACLS Provider Advanced Cardiovascular Life Support
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: BLS & High-Quality CPR Foundation
1.1 Chest Compression Mechanics & Performance Metrics 1.2 Chest Compression Fraction & Interruptions 1.3 Two-Rescuer Rotation & Fatigue Prevention 1.4 AED Operation & Special Resuscitation Circumstances
2 Chapter 2: ACLS Adult Cardiac Arrest Algorithm
2.1 Cardiac Arrest Recognition & Systematic Approach 2.2 VF/pVT Management & Defibrillation Energy Protocols 2.3 Asystole & PEA Management 2.4 Epinephrine Dosing & Pharmacodynamics in Arrest 2.5 Antiarrhythmic Drugs: Amiodarone & Lidocaine in Refractory VF/pVT 2.6 Reversible Causes of Arrest: The H's 2.7 Reversible Causes of Arrest: The T's 2.8 Physiological Monitoring & CPR Quality Metrics
3 Chapter 3: Bradycardia Algorithm
3.1 Symptomatic Bradycardia Assessment & Instability Criteria 3.2 Atropine Dosing, Indications & Block Limitations 3.3 Transcutaneous Pacing (TCP) Operation & Management 3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
4 Chapter 4: Tachycardia Algorithm
4.1 Tachycardia Triage: Stable vs. Unstable Assessment 4.2 Synchronized Cardioversion Indications, Energy Doses & Sync Mechanics 4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol 4.4 Stable Wide-Complex Tachycardia & Antiarrhythmic Infusions 4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
5 Chapter 5: Acute Coronary Syndrome (ACS)
5.1 ACS Identification, EMS & ED Triage 5.2 Initial ED & Prehospital Pharmacotherapy 5.3 STEMI vs. NSTE-ACS Risk Stratification & Biomarkers 5.4 Reperfusion Strategies & Quality Benchmark Time Goals
6 Chapter 6: Acute Ischemic Stroke
6.1 Stroke Recognition & Out-of-Hospital Assessment 6.2 Emergency Department Evaluation & Diagnostic Time Goals 6.3 Fibrinolytic Therapy & Blood Pressure Management 6.4 Endovascular Therapy (EVT) & Post-Acute Care
7 Chapter 7: Post–Cardiac Arrest Care
7.1 Immediate Post-ROSC Airway & Respiratory Optimization 7.2 Hemodynamic Management & MAP Optimization 7.3 Temperature Control & Targeted Temperature Management (TTM) 7.4 Emergent Coronary Angiography & Multimodal Neuroprognostication
8 Chapter 8: Airway Management & Pharmacology
8.1 Basic Airway Adjuncts & Bag-Mask Ventilation 8.2 Advanced Airways: Supraglottic Devices & Endotracheal Intubation 8.3 Continuous Waveform Capnography 8.4 ACLS Emergency Drug Reference & Administration Routes
9 Chapter 9: High-Performance Team Dynamics & Special Circumstances
9.1 High-Performance Team Dynamics & Communication 9.2 Resuscitation Debriefing & Quality Improvement Metrics 9.3 Special Arrest Circumstances: Cardiac Arrest in Pregnancy 9.4 Special Arrest Circumstances: Opioids, Anaphylaxis, Drowning & Hypothermia
4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol
Key Takeaways Explain This Topic AI
Vagal maneuvers, particularly the modified Valsalva maneuver, are first-line non-pharmacological therapy for stable regular narrow-complex SVT.
If vagal maneuvers fail, administer Adenosine as a 6 mg rapid IV push immediately followed by a 20 mL saline flush and extremity elevation.
If SVT does not convert within 1 to 2 minutes, administer a second dose of 12 mg Adenosine rapid IV push with flush.
Adenosine's extremely short half-life (<10 seconds) mandates rapid IV push and immediate flushing.
Patients must be warned of transient side effects including chest pressure, flushing, dyspnea, and a brief period of asystole.
Last updated: July 2026
Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol
When the initial assessment determines that a patient with a tachyarrhythmia is hemodynamically stable (lacking hypotension, altered mental status, signs of shock, ischemic chest pain, or acute heart failure), the urgency shifts from immediate electrical intervention to a deliberate, pharmacological approach.
If the subsequent ECG analysis reveals a regular, narrow QRS complex (<0.12 seconds) , the diagnosis is most likely Supraventricular Tachycardia (SVT). The management of stable SVT follows a stepwise progression, beginning with simple physical maneuvers and advancing to specific antiarrhythmic medications, primarily adenosine.
First-Line Therapy: Vagal Maneuvers
Vagal maneuvers are the initial intervention of choice for terminating stable SVT. These physical actions stimulate the vagus nerve (cranial nerve X), which is a major component of the parasympathetic nervous system. Vagal stimulation releases acetylcholine at the atrioventricular (AV) node, temporarily slowing conduction and increasing the refractory period. Because many SVTs (like AV nodal reentrant tachycardia) rely on the AV node to maintain their circuit, this brief block can successfully break the tachycardia and allow the normal sinus node to resume control.
Types of Vagal Maneuvers
Valsalva Maneuver: This is the most common and often most effective method. The patient is instructed to forcibly exhale against a closed glottis, essentially bearing down as if having a bowel movement. A standardized way to achieve this is asking the patient to blow into a 10cc syringe forcefully enough to push the plunger back, maintaining the pressure for 10 to 15 seconds.
Modified Valsalva Maneuver: Recent studies, such as the REVERT trial, have shown that modifying the standard Valsalva significantly increases its success rate.
Technique: The patient performs the standard Valsalva strain (blowing into a syringe) for 15 seconds while seated semi-recumbent. Immediately after the strain, the patient is laid flat (supine), and their legs are passively raised to a 45-degree angle by a provider for 15 seconds. This position change rapidly increases venous return to the heart, maximizing vagal tone and improving conversion rates.
Carotid Sinus Massage: This involves applying firm, circular pressure to the carotid sinus (located just below the angle of the jaw) for 5 to 10 seconds. Important Caveats: This should only be performed by a physician. It is contraindicated in patients with known carotid bruits, a history of transient ischemic attacks (TIAs), or stroke, due to the risk of dislodging an atherosclerotic plaque.
Providers should continuously monitor the ECG during vagal maneuvers. If the rhythm successfully converts to normal sinus rhythm, further interventions are unnecessary, though the patient should remain under observation.
The Adenosine Protocol
If vagal maneuvers are unsuccessful, the next step in the algorithm is the administration of adenosine. Adenosine is a unique antiarrhythmic agent; it is an endogenous purine nucleoside that acts primarily on the AV node.
Mechanism of Action
Adenosine causes profound, temporary AV nodal blockade. By briefly halting electrical conduction through the AV node, it effectively "resets" the electrical system, interrupting the reentrant circuits that drive SVT.
Crucial Pharmacokinetics: The Need for Speed
The most important characteristic of adenosine is its incredibly short half-life—typically less than 10 seconds in the blood. It is rapidly metabolized by enzymes in the red blood cells and endothelial cells.
Because it degrades so quickly, the method of administration is critical. If given slowly, it will be destroyed before it ever reaches the heart, rendering it entirely ineffective. Therefore, the "Rapid IV Push" technique is mandatory.
Standard Dosing and Administration Protocol
Preparation:
Ensure the patient is on a continuous cardiac monitor, and a defibrillator is immediately available in the room.
Establish reliable IV access, preferably in a large proximal vein (e.g., the antecubital fossa). A central line is not required but necessitates lower doses if present.
Draw up the adenosine and a separate 20 mL syringe of normal saline flush.
Ideally, use a stopcock or a Y-connector on the IV line to allow immediate flushing.
First Dose:
Administer 6 mg of Adenosine as a very rapid IV push (over 1 to 3 seconds).
Immediate Flush: Immediately follow the adenosine with a rapid 20 mL normal saline flush .
Elevation: Immediately elevate the extremity with the IV access for 10-20 seconds to utilize gravity to facilitate rapid delivery to the central circulation.
Assessment and Second Dose:
Observe the monitor continuously.
If the SVT does not convert within 1 to 2 minutes after the first dose, prepare the second dose.
Administer 12 mg of Adenosine using the exact same rapid push, flush, and elevate technique.
Expected Side Effects and Patient Preparation
Before administering adenosine, it is crucial to warn the patient about its effects. Because adenosine causes temporary AV block, it frequently produces a brief period of asystole (a flatline on the ECG) lasting for a few seconds before the sinus node takes over.
This brief cessation of cardiac activity, along with the drug's vasodilatory properties, causes intense, though transient, side effects. Patients often report:
A sudden sense of impending doom or extreme anxiety.
Intense chest pressure or heaviness.
Flushing of the face and neck.
Dyspnea or shortness of breath.
Providers must reassure the patient that these sensations are normal, expected, and will resolve completely within seconds as the drug rapidly metabolizes.